| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.1 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |